Mitesh J. Borad

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• 52Treatment patterns among patients with extrahepatic cholangiocarcinoma with autoimmune conditions: a retrospective study

  The Oncologist · 2026-06-01

• 50Real-world characteristics and outcomes of durvalumab + gemcitabine + cisplatin in patients with cholangiocarcinoma in the US

  The Oncologist · 2026-06-01

• Survival outcomes with matched targeted therapy in advanced biliary tract cancer: a large global cohort analysis

  npj Precision Oncology · 2026-05-05

• Abstract 4378: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models

  Cancer Research · 2026-04-03

• Abstract 7124: Resistance to the SFK inhibitor NXP900 in cholangiocarcinoma is characterized by IL13RA2-AKT signaling and can be overcome by combination therapy

  Cancer Research · 2026-04-03

• Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer

  JCO Precision Oncology · 2026-04-01

• Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer

  Scientific Reports · 2026-03-11 · 1 citations

• Multiomics-driven discovery of predictive biomarkers and strategies to overcome resistance to SFK-YAP inhibition in cholangiocarcinoma

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-01-23

• Clinico-genomic characterization of <i>TP53</i> / <i>CDKN2A</i> co-alteration and its prognostic value in biliary tract cancer (BTC).

  Journal of Clinical Oncology · 2026-01-10

• Impact of infusion timing (IT) on survival outcomes across gastrointestinal (GI) malignancies: A multicenter analysis of circadian rhythm (CR) effects on immune checkpoint inhibitor (ICI) activity.

  Journal of Clinical Oncology · 2026-01-10

• Leveraging large language models (LLM) to guide adjuvant chemotherapy (AC) recommendations in stage III colorectal cancer (CRC).

  Journal of Clinical Oncology · 2026-01-10

• Prognostic role of PIK3CA and co-alterations in advanced biliary tract cancer: A multicenter retrospective analysis.

  Journal of Clinical Oncology · 2026-01-10

• Single-arm phase 2 study of the FGFR inhibitor futibatinib (Futi) in combination with pembrolizumab (Pem) in patients with FGF19 expressing advanced or metastatic hepatocellular carcinoma (aHCC).

  Journal of Clinical Oncology · 2026-01-10

• Efficacy and safety of lirafugratinib in <i>FGFRi</i> -naïve cholangiocarcinoma (CCA) patients harboring <i>FGFR2</i> fusions/rearrangements ( <i>FGFR2</i> f/r).

  Journal of Clinical Oncology · 2026-01-10 · 2 citations

• Molecular characterization of resected non-metastatic pancreatic cancer (PC) based on <i>KRAS</i> status.

  Journal of Clinical Oncology · 2026-01-10

• Use of transcriptomic signatures of <i>RAD51</i> and <i>GATA6</i> to predict real-world overall survival with platinum therapy in <i>BRCA/PALB2</i> wild-type metastatic pancreatic cancer.

  Journal of Clinical Oncology · 2026-01-10

• Immune related adverse events (irAEs) in Lynch vs non-Lynch microsatellite instability-high (MSI-high) gastrointestinal (GI) cancers: A retrospective cohort study.

  Journal of Clinical Oncology · 2026-01-10

• Prognostic value of perioperative circulating tumor DNA (ctDNA) in endometrial cancer with high-risk features: a prospective observational study

  European Journal of Surgical Oncology · 2026-01-06

• Identification of Novel TERT Promoter Mutations in Chronic Hepatitis B-Induced HCC Patients in Burkina Faso

  American Journal of Molecular Biology · 2026-01-01

• MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN Response

  Clinical Cancer Research · 2025-12-29 · 3 citations